- Supported exchanges /
- KO /
- 005500.KO
Samjin Pharm (005500 KO) stock market data APIs
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Samjin Pharm Financial Data Overview
| 18920 | |
| 18410 | |
| - | |
| 18990 | |
| 18410 | |
| 16690-23350 | |
| 237 018 M | |
| 12 527 K | |
| 274 032 M | |
| 358.5374 | |
| 0.0423 | |
| 0.266 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Samjin Pharm Fundamental Data is available in our Financial Data APIs
- Net Revenue 274 032 M
- EBITDA 33 000 M
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Samjin Pharm Earnings via APIs
- Latest Release 2024-11-12
- EPS/Forecast NaN
Get Samjin Pharm End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
